DiNAQOR is a global gene therapy platform company focused on advancing novel solutions for patients suffering from heart disease. We are headquartered in Pfäffikon, Switzerland, with additional presence in London, England and Boston, Massachusetts.
As of now, only 5% of so-called rare diseases (orphan diseases) have an FDA-approved treatment available to patients. Rare diseases are defined as those affecting fewer than 1 in 200.000 people with almost 80% of all rare diseases being of genetic nature. With recent progress in gene-editing technologies, including breakthroughs …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.